Protect Pharmaceutical (PRTT) Inactive 10-K2013 FY Annual report

Filed: 14 Apr 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: Asof, attributed, bee, Companythe, East, forseeable, leaving

Removed: Abajian, abandon, accept, acceptance, active, adversely, affected, algae, alternate, arbitration, arise, assign, assimilate, assimilating, assist, attained, attempting, attention, attest, attestation, attract, Attracting, attractive, bank, began, biopharmaceutical, brought, build, Caldwell, capable, capturing, care, carefully, case, Certification, challenging, characterized, charged, circumvent, collaborate, collaboration, collaborator, commissioned, commit, commonplace, compare, competitor, complexity, concentration, conclude, Conducting, confidence, conflict, consisting, consuming, contracting, convenience, copy, costly, cover, coverage, created, critical, cultivation, decide, declare, defense, delaying, delinquent, demonstrated, deny, Depending, depicted, deprive, derived, deterring, detriment, devote, dictated, difficult, diligently, diminish, diminished, discontinue, discover, discovered, discovering, dispute, diversion, divert, division, eliminating, encounter, energy, engineer, enjoy, enrollment, entitle, equivalent, exert, exhaust, exhibit, expanding, expend, expensive, experienced, expertise, expressed, extreme, face, favor, feasibility, finalizing, flow, force, forced, forego, foregoing, formed, formulary, founder, gain, gaining, generated, generating, geographical, great, grow, healthcare, hiring, immaterial, impair, implemented, impossible, inability, Inclusion, indemnification, influenced, infringing, inherently, instituted, institution, insurance, intense, intensify, interfere, international, introduction, invalidate, invest, jeopardized, joined, joint, justify, lack, lead, leading, legislation, limiting, liquidate, litigation, loan, locate, lose, losing, managed, manufacturer, MD, Media, Medicare, mitigate, negatively, novelty, offering, optimization, organize, organizing, OTCBB, Oxycodeine, parallel, participating, penetration, perception, performed, pharmacist, pharmacoeconomic, physically, Pink, placebo, planned, Policing, political, preclude, preliminarily, premature, premium, preparing, prescribed, priority, proceeding, profitability, prohibited, promptly, promulgate, published, pursue, quarter, quarterly, questionable, quickly, quota, rapid, reached, refilled, refusing, reimbursement, relationship, relocated, reluctant, repaid, repeat, replacement, replicate, represent, requisite, resolved, resulting, risky, saleable, senior, staffing, stay, strategic, strength, substandard, succeed, suffer, suit, support, technical, terminate, terminated, termination, timing, today, track, trial, turnover, usage, variety, viewed, volatile, volatility, vote, West, William

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PRTT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Protect Pharmaceutical Corporation (the “Company”) on Form 10-K for the period ending December 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I,Geoff Williams, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ GEOFF WILLIAMS

Geoff Williams

Chief Executive Officer

April 14, 2014

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. The foregoing certifications are accompanying the Company's Form 10-K solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of the Form 10-K or as a separate disclosure document.